AbbVie Inc. (ABBV) — Q2 2026 Earnings Preview

Upcoming Earnings: Q2 2026 | Reporting July 31, 2026 Prepared: July 30, 2026

Sector: Drug Manufacturers — General Last Earnings: April 29, 2026 (Q1 2026)

1. Earnings Preview

Key Takeaway: Setup leans toward a beat — consensus is a manageable bar, guidance was raised post-Q1, and the immunology growth engine (Skyrizi + Rinvoq) continues to outpace expectations — but a $291M pre-disclosed IPR&D charge (Apogee milestone) has already reset the EPS baseline, so the real swing factor is whether Skyrizi's Q2 revenue can clear the ~$5.44B consensus hurdle.

Heading into Q2 2026, AbbVie's bar is achievable but not trivial: consensus sits at ~$16.77B in revenue and ~$3.61 in adjusted EPS (the latter already reflecting the $0.17 per-share drag from the $291M Apogee-related IPR&D charge disclosed via 8-K on July 6). Management raised full-year revenue guidance by $300M to ~$67.3B after Q1's broad-based beat, and explicitly stated they see upside to sell-side consensus peak estimates for both Skyrizi and Rinvoq — a posture that is more confident than cautious. Estimate revisions have been modestly positive since the Q1 print: the Q2 2026 revenue consensus has held near $16.77B (essentially flat vs. the $16.78B baseline set 5 days post-Q1 earnings), while the FY2026 EPS consensus has drifted down to ~$14.09 from ~$14.30 post-Q1, entirely explained by the two disclosed IPR&D charges ($744M Q1 + $291M Q2 = $1.035B cumulative). The stock has been a standout performer since the April 29 print, up ~26% vs. ~4% for the S&P 500 and ~18% for XBI, driven by the June 22 Apogee acquisition announcement and sustained immunology momentum — meaning some beat is already priced in. The key wildcard is aesthetics: Juvederm filler trends remain under pressure from macro headwinds, and any further deterioration vs. the ~$1.27B consensus could weigh on the print even if immunology and neuroscience deliver.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a moderate bar — Skyrizi at ~$5.44B is the biggest swing factor given management's explicit upside commentary, while aesthetics (~$1.27B) remains the key downside risk given persistent macro headwinds on fillers.

Table 1 — Q2 2026 Current Quarter Snapshot

Source: Visible Alpha Consensus and Actuals Data. Q2 2026 Adj. EPS consensus of $3.61 reflects the $0.17/share impact of the $291M Apogee-related IPR&D charge pre-disclosed via 8-K on July 6, 2026. Guidance for Q2 2026 revenue (~$16.7B) and EPS ($3.74–$3.78 ex-IPR&D; $3.57–$3.61 incl. IPR&D) was provided on the Q1 2026 earnings call (April 29, 2026) and subsequently updated via 8-K.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Top 2 KPIs: Total Revenue & Skyrizi Revenue

Pattern: AbbVie has beaten consensus on both Total Revenue and Skyrizi in each of the last 8 quarters, with Skyrizi surprise magnitude averaging ~5–6% — a consistent pattern that sets a high bar for the market's expectations heading into Q2 2026. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Management raised FY2026 revenue and key product guidance after Q1, and tone remains highly confident — the only post-earnings guidance revision was a downward EPS adjustment on July 6 due to a pre-disclosed $291M Apogee IPR&D charge, which is non-operational and already reflected in consensus.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 revenue have been essentially flat since the Q1 print, while FY2026 EPS estimates have drifted lower by ~1.5% — entirely explained by the two disclosed IPR&D charges rather than any deterioration in underlying business momentum. Skyrizi and Rinvoq FY estimates sit modestly above guidance, consistent with management's upside commentary.

Source: Visible Alpha Consensus and Actuals Data. Baseline estimates as of May 5, 2026 (5 trading days post-Q1 earnings). The EPS estimate decline of ~4% for Q2 and ~1.5% for FY2026 is entirely attributable to the $291M Apogee IPR&D charge disclosed July 6, 2026 — not to any deterioration in underlying business estimates. Revenue and product-level estimates have been remarkably stable, consistent with management's raised guidance and upside commentary.

5. Stock Performance

Key Takeaway: ABBV has dramatically outperformed both the S&P 500 (+26% vs. +4%) and XBI (+26% vs. +18%) since the Q1 2026 earnings print, driven primarily by the June 22 Apogee acquisition announcement and sustained immunology momentum — suggesting the market is pricing in continued execution, leaving less room for error on the print.

ABBV vs. XBI vs. S&P 500 — Indexed to 100 at April 29, 2026 (Q1 2026 Earnings Date). Source: Yahoo Finance / Stock Price Data.

Key Events Since Q1 2026 Earnings (April 29, 2026):

• April 29, 2026: Q1 2026 earnings beat; FY2026 revenue guidance raised to ~$67.3B; stock +<1% on the day (beat partially anticipated given pre-disclosed IPR&D charge).
• June 22, 2026: AbbVie announces acquisition of Apogee Therapeutics for ~$10.9B ($135.11/share); stock surged ~6% on the day, adding immunology depth in atopic dermatitis (zumilokibart/APG777) and asthma (APG273).
• July 2, 2026: Stock reached ~$261, near-term high, up ~28% from earnings date.
• July 6, 2026: 8-K filed disclosing $291M Q2 IPR&D charge (Apogee milestone); Q2 EPS guidance revised to $3.57–$3.61 (from $3.74–$3.78 ex-IPR&D); stock pulled back modestly.

ABBV return since Q1 earnings: +26.2% | SPY: +4.2% | XBI: +17.5%. Source: Yahoo Finance / Stock Price Data.

6. Material News & Developments

Key Takeaway: The Apogee Therapeutics acquisition ($10.9B, June 22) is the most consequential development since Q1 earnings — it deepens AbbVie's immunology pipeline in atopic dermatitis and asthma and triggered the stock's largest single-day move of the inter-earnings period, but also introduced the $291M IPR&D charge that reset the Q2 EPS baseline.

• June 22, 2026 — Apogee Therapeutics Acquisition Announced ($10.9B): AbbVie agreed to acquire Apogee Therapeutics for $135.11/share in cash (~$10.9B total equity value). Lead asset is zumilokibart (APG777), a half-life extended anti-IL-13 mAb in late-stage development for atopic dermatitis (Phase 2 showed ~2/3 of patients achieving significant skin clearance at 16 weeks with quarterly or twice-yearly dosing) and asthma (APG273 combination with anti-TSLP APG333). Transaction expected to close Q3 2026; accretive to adj. EPS beginning 2032. Implication: Adds a potential mega-blockbuster IL-13 asset to compete in the large atopic dermatitis market; also triggered the $291M Q2 IPR&D milestone charge that reset EPS guidance.
• July 6, 2026 — Q2 2026 EPS Guidance Revised via 8-K: AbbVie disclosed a $291M acquired IPR&D and milestones expense for Q2 2026 (related to Apogee), reducing Q2 adj. EPS guidance by $0.17/share to $3.57–$3.61 and FY2026 adj. EPS guidance to $13.91–$14.11 (cumulative IPR&D of $1.035B). Implication: Non-operational; consensus has already reset to reflect this charge. The underlying business guidance (revenue, product-level) was unchanged.
• April 27, 2026 — Skyrizi Subcutaneous Induction BLA Submitted for Crohn's Disease: AbbVie submitted a U.S. regulatory application for Skyrizi subcutaneous induction in Crohn's disease, supported by Phase 3 AFFIRM study data showing large efficacy deltas vs. placebo in treatment-naive/frontline patients. FDA approval anticipated later in 2026. Implication: Subcu induction would further strengthen Skyrizi's frontline IBD positioning and reduce IV access barriers; a potential label expansion catalyst in H2 2026.
• April 29, 2026 — Q1 2026 Earnings Beat; Guidance Raised: AbbVie reported Q1 2026 results exceeding expectations across immunology and neuroscience. FY2026 revenue guidance raised by $300M to ~$67.3B; Skyrizi +$100M to $21.6B; Rinvoq +$100M to $10.2B; Neuroscience +$100M to $12.6B. Management explicitly stated they see upside to consensus peak estimates for Skyrizi and Rinvoq. Implication: Establishes a confident tone heading into Q2; management's upside commentary on peak estimates is a bullish signal for the long-term growth narrative.
• April 29, 2026 — Skyrizi + ABBV-382 Combination Data (Crohn's Platform Study): Interim data showed endoscopic remission rates doubling vs. either monotherapy arm at weeks 12 and 24 in a highly refractory population (including Skyrizi failures). No additive adverse events. Phase IIb studies planned imminently. Implication: Positions AbbVie's combination platform as the next-generation IBD standard of care; a potential multi-billion-dollar opportunity beyond current Skyrizi monotherapy.
• April 2026 — TrenibotE FDA Complete Response Letter (Aesthetics): FDA issued a CRL for the trenibotE BLA citing manufacturing process questions only; no safety, efficacy, or labeling concerns; no additional clinical trials required. International approvals (Europe, Canada, Japan) remain on track for 2026. Implication: Delays U.S. launch of the fast-acting short-duration toxin; modest negative for aesthetics near-term but not a fundamental setback given the manufacturing-only nature of the CRL.
• Post-ASCO 2026 — Oncology Pipeline Momentum: ABBV-706 (SEZ6-directed ADC) showed strong Phase 1 data in second-line SCLC with a high response rate and unprecedented median OS; Phase 3 in relapsed/refractory SCLC initiated. ABBV-969 (PSMA/STEAP1 bispecific ADC) showed strong Phase 1 data in heavily pretreated prostate cancer; rapid Phase 3 initiation planned. Etentamig regulatory submission now expected by end of 2026 (earlier than prior guidance). Implication: Oncology pipeline gaining investor attention; management views sell-side models as significantly undervaluing Tmab-A and etentamig (each ~$1B consensus vs. management's multibillion-dollar view).
• Q1 2026 — Obesity Pipeline: ABBV-295 Amylin Analog Early Data: Phase 1 MAD study completed showing dose-dependent, clinically meaningful weight loss (~10% at 12 weeks) in a predominantly male, lower-BMI population with no serious adverse events. Phase 1B and Phase 2 studies confirmed as next steps targeting higher BMI populations. Implication: Emerging obesity pipeline adds a new long-term growth optionality narrative; management views aesthetics channel relationships with injectors as a natural commercial fit.

7. Peer Commentaries — Read-Through for Q2 2026

Key Takeaway: Peer Q2 2026 earnings calls (JNJ, BMY, GSK, AZN, BIIB) and Q1 2026 calls (PFE, GILD) provide broadly constructive read-throughs for AbbVie's immunology and neuroscience franchises — the IL-23 market is growing rapidly (JNJ's Tremfya hit a $2B quarter), the neuroscience market is healthy (Spravato +40%, Caplyta +71%), and aesthetics/injectables demand signals are mixed. The most important read-through is JNJ's Tremfya/Icodet commentary, which confirms robust IBD market growth that should benefit Skyrizi.

Johnson & Johnson (JNJ) — Q2 2026 Earnings (July 15, 2026)

Relevance: HIGH — Direct read-through for Skyrizi (IL-23 in IBD/psoriasis) and neuroscience (Spravato vs. Vraylar/psychiatry market).

• IL-23 IBD Market Growing Rapidly — Bullish for Skyrizi: JNJ's Tremfya hit its first-ever $2B quarter with 71% growth, driven primarily by IBD (ulcerative colitis and Crohn's disease). JNJ claims 58% induction share in UC and >50% in Crohn's among IL-23 therapies. This confirms the IBD market is expanding rapidly and that IL-23 is becoming the dominant mechanism — a direct positive read-through for Skyrizi, which competes in the same IL-23 class and has been gaining frontline share.
• Icodet (Oral IL-23) Launch Momentum — Market Expanding, Not Cannibalizing: JNJ's oral IL-23 Icodet (approved for plaque psoriasis) has seen >10,000 patients initiate therapy since launch, with >50% commercial coverage within 90 days. JNJ explicitly positions Icodet as the 'first choice systemic' for patients cycling off topicals, while Tremfya is the 'first choice biologic' for patients with psoriatic arthritis involvement. This co-positioning framework is consistent with AbbVie management's view that Icodet is primarily market-expanding rather than displacing Skyrizi, supporting Skyrizi's continued share gains in the biologic segment.
• Tremfya Perianal Fistulizing Crohn's Data — Competitive Signal: JNJ presented new 'Fusion' data showing Tremfya is the first positive study in >20 years in adults with active perianal fistulizing Crohn's, claiming it is the 'only IL-23 to demonstrate efficacy in this setting.' This is a competitive differentiation claim vs. Skyrizi in a severe IBD subpopulation affecting ~25% of Crohn's patients. AbbVie will need to address this in its own pipeline strategy.
• Neuroscience — Spravato +40%, Caplyta +71%: JNJ's Spravato (esketamine) grew 40% with strong sequential growth of 24.8%, and Caplyta (lumateperone) grew 71% in adjunctive MDD with new patient starts up 122% vs. prior year. These strong neuroscience market growth signals are broadly positive for AbbVie's neuroscience portfolio (Vraylar, migraine franchise), confirming robust underlying demand in psychiatry and CNS.
• Stelara Biosimilar Erosion — Confirms Humira LOE Playbook: Stelara declined 55.7% due to biosimilar competition, now representing only 4% of JNJ's innovative medicine business. This confirms the biosimilar erosion playbook that AbbVie has already navigated with Humira, and validates AbbVie's successful transition to Skyrizi/Rinvoq.

Bristol Myers Squibb (BMY) — Q2 2026 Earnings (July 30, 2026)

Relevance: MODERATE — Read-through for immunology (psoriasis/lupus market dynamics) and neuroscience (schizophrenia market with Cobenfi vs. Vraylar).

• Sotyktu (TYK2) in Psoriasis Growing 23% — Confirms Psoriasis Market Expansion: BMS's TYK2 inhibitor Sotyktu grew 23% globally, with BMS supporting a new psoriatic arthritis indication and expecting Phase 3 readouts in lupus later this year. The psoriasis market continues to grow with multiple mechanisms (IL-23, TYK2, oral IL-23) expanding the addressable patient pool — broadly positive for Skyrizi's continued share gains.
• Cobenfi (Schizophrenia) Growing 81% — Competitive Signal for Vraylar: BMS's Cobenfi (KarXT) grew 81% to $63M in schizophrenia, with BMS noting 'deeply entrenched prescribing behaviors' as the key challenge to accelerating new patient starts. Cobenfi is a muscarinic agonist with a differentiated mechanism vs. Vraylar (D2/D3 partial agonist). The schizophrenia market is growing but competitive; Vraylar's established position and broader label (bipolar, adjunctive MDD) provides some insulation. BMS also noted Phase 3 Balsam studies for Cobenfi in bipolar I disorder reading out H1 2027 — a future competitive threat to Vraylar's bipolar franchise.
• Lupus Market Dynamics — Relevant to Rinvoq Pipeline: BMS expressed high confidence in Sotyktu's Phase 3 SLE data (reading out later this year), citing a large and compelling Phase 2 study. The lupus market is characterized by significant unmet need for treatments that reduce steroid dependence. Rinvoq has a lupus label and is expanding in this indication — the competitive dynamics from Sotyktu in SLE are worth monitoring.
• Growth Portfolio Up 14% — Healthy Pharma Demand Environment: BMS's growth portfolio grew 14% with 10 products achieving double-digit growth, and the company raised FY2026 revenue and EPS guidance. This confirms a healthy demand environment for innovative medicines broadly, a positive macro read-through for AbbVie.

GSK — Q2 2026 Earnings (July 28, 2026)

Relevance: MODERATE — Read-through for immunology market dynamics (respiratory/COPD) and oncology ADC competitive landscape.

• Specialty Medicines Growing 14% — Positive Pharma Demand Signal: GSK's specialty medicines grew 14% in Q2, with overall sales up 5%. The strong performance across innovative medicines confirms robust demand for specialty pharma broadly.
• Nucala (IL-5) COPD Launch Gaining Traction: GSK's Nucala saw new-to-brand prescriptions up 69% with COPD driving >70% of growth. This confirms the respiratory/immunology market is expanding into COPD — a large new indication (400M patients globally) that AbbVie does not currently address but that validates the broader immunology market growth thesis.
• B7-H3 ADC (Resources) Phase 3 Positive in SCLC — Competitive Signal for ABBV-706: GSK's partner Hanso announced that the Artemis 008 Phase 3 China study for its B7-H3 ADC met its primary endpoint in second-line SCLC, marking the 'first positive Phase 3 overall survival data for a B7H3-directed ADC in any tumor type.' AbbVie's ABBV-706 is a SEZ6-directed ADC (different target) in SCLC with strong Phase 1 data and an ongoing Phase 3 — the GSK/Hanso data validates the SCLC ADC opportunity but also signals increasing competition in this space.
• General Medicines Down 9% — LOE Headwinds Confirmed: GSK's general medicines declined 9% due to LOE headwinds and pricing pressure on older assets. This is consistent with the broader industry LOE dynamic that AbbVie has already navigated with Humira.

AstraZeneca (AZN) — Q2 2026 Earnings (July 27, 2026)

Relevance: LOW-MODERATE — Limited direct read-through; AZN's immunology focus is respiratory (IL-5, TSLP, IL-33) rather than IBD/psoriasis. Oncology ADC commentary is relevant to AbbVie's oncology pipeline.

• Respiratory & Immunology Growing 11% in Q2 — Broad Immunology Market Healthy: AZN's respiratory and immunology segment grew 11% in Q2, driven by Fasenra (+13%) and Saphnelo (+24% in SLE). The broad immunology market remains healthy, a positive macro read-through for AbbVie's immunology franchise.
• Oncology Total Revenue +15% H1 2026 — Strong Oncology Market: AZN's oncology revenues grew 15% in H1 2026 to $14.1B, with notable growth in the U.S. (+18%) and Europe (+16%). The strong oncology market growth is a positive read-through for AbbVie's expanding oncology pipeline (etentamig, ABBV-706, ABBV-969).
• ADC Pipeline Advancing Rapidly — Competitive Landscape Intensifying: AZN announced positive Phase 3 data for Sony Vedotin (Claudin 18.2 ADC) in gastric cancer, with peak revenue estimated at $3–$5B. The ADC space is becoming increasingly competitive, which is relevant context for AbbVie's own ADC pipeline (ABBV-706, ABBV-969, Tmab-A).
• MFN Pricing Dynamics — AZN's Pricing Approach Evolving: AZN noted its pricing approach has 'evolved in response to MFN,' with the U.S. now referencing a basket of countries. This is a broader industry pricing headwind that AbbVie also faces, though AbbVie's immunology assets (Skyrizi, Rinvoq) are not yet subject to IRA negotiation.

Biogen (BIIB) — Q2 2026 Earnings (July 29, 2026)

Relevance: LOW-MODERATE — Limited direct overlap; read-through primarily for neuroscience market dynamics (Alzheimer's, MS) and autoimmune market expansion.

• Neuroscience Market Healthy — Leqembi Growing 15% YoY: Biogen's Leqembi (Alzheimer's) grew 15% YoY to $184M, with FDA approval for subcutaneous initiation (Icheic) expected to broaden patient eligibility. The neuroscience market is growing, with home dosing options expanding access — a broadly positive read-through for AbbVie's neuroscience portfolio (Vraylar, migraine, Parkinson's).
• Lupus Market Opportunity Highlighted — $20B+ Total Market: Biogen highlighted the lupus market as a >$20B total opportunity, with its initial addressable market from pipeline projected at $8B. The company has five Phase 3 readouts expected in the next four quarters across SLE and CLL. This confirms the lupus market is a major growth opportunity — relevant to Rinvoq's expanding label in SLE.
• Biogen Raised FY2026 Revenue Guidance to Mid-Single-Digit Growth: Biogen raised its total revenue guidance from a mid-single-digit decrease to a mid-single-digit increase, driven by the Apellis acquisition (Syfovre, Empaveli). This positive guidance revision in the broader biotech space is a constructive macro signal.

Pfizer (PFE) — Q1 2026 Earnings (May 5, 2026)

Relevance: MODERATE — Read-through for migraine market (Nurtec vs. Ubrelvy/Qulipta) and oncology ADC competitive landscape.

• Nurtec (Oral CGRP) Growing 41% Operationally — Migraine Market Expanding: Pfizer's Nurtec grew 41% operationally, with management noting that only 60% of triptan prescribers have yet to prescribe an oral CGRP — indicating substantial headroom for growth in the oral CGRP class. This is a positive read-through for AbbVie's migraine franchise (Ubrelvy, Qulipta), confirming the oral CGRP market is still in early penetration with significant runway.
• Immunology Pipeline — Tilrekimig Trispecific in Atopic Dermatitis: Pfizer announced a positive Phase 2 readout for tilrekimig (IL-4/IL-13/TSLP trispecific) in atopic dermatitis, asthma, and COPD. This is a future competitive signal for AbbVie's newly acquired Apogee assets (zumilokibart/APG777 targets IL-13) in atopic dermatitis, though the timelines are still early-stage.

Gilead Sciences (GILD) — Q1 2026 Earnings (May 7, 2026)

Relevance: LOW — Limited direct overlap with AbbVie's core franchises; read-through primarily for autoimmune market dynamics and oncology ADC competitive landscape.

• Inflammation Pipeline Expanding — Oral Alpha-4 Beta-7 Inhibitor in IBD: Gilead is developing GS-1427 (emvistagrast), an oral alpha-4 beta-7 inhibitor for IBD (including ulcerative colitis), with Phase 2 SWIFT study updates expected in 2026. This is a future competitive signal for Skyrizi in IBD, though the mechanism (gut-selective integrin inhibitor) is different from IL-23. The development of oral IBD therapies broadly is a long-term competitive dynamic to monitor.
• Autoimmune Market — BCMA CD3 Bispecific for Durable Immune Reset: Gilead's pending acquisition of Ouro Medicines (gamgertamig, BCMA CD3 bispecific) targets a 'durable immune reset' in autoimmune diseases, with Phase 3 registrational trials targeted as early as 2027 in >20 autoimmune diseases. This represents a longer-term competitive dynamic for the immunology market broadly, though the mechanism and patient population differ from AbbVie's current Skyrizi/Rinvoq franchise.

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells by executives or directors in the last 60 days — all transactions are routine equity award grants (code A) to directors, which are non-discretionary and carry no informational signal. The absence of any open-market selling by insiders ahead of the print is a mild positive.

Note: All transactions in the lookback period (May 1 – July 30, 2026) are Form 4 code 'A' (Award/Grant) transactions — routine director equity compensation grants. There are no open-market purchases (code P) or open-market sales (code S) to report. The table below shows the director grants for completeness.

Source: SEC Form 4 Filings Database (Insider Transaction Data). All transactions are equity award grants (Code A) — routine director compensation. No open-market buys (Code P) or open-market sales (Code S) were filed in the May 1 – July 30, 2026 window. The absence of discretionary insider selling ahead of the Q2 2026 print is a mild positive signal.

— End of Document —